Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1994-02-03
1995-06-20
Stone, Jacqueline
Drug, bio-affecting and body treating compositions
Lymphokine
424 852, 514 2, 514 8, A61K 4505, A61K 3702
Patent
active
054259401
ABSTRACT:
Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.
REFERENCES:
patent: 4401756 (1983-08-01), Gillis
patent: 4447355 (1984-05-01), Sakamoto et al.
patent: 4518584 (1985-05-01), Mark et al.
patent: 4530787 (1985-07-01), Shaked et al.
patent: 4569790 (1986-02-01), Koths et al.
patent: 4572798 (1986-02-01), Koths et al.
patent: 4588585 (1986-05-01), Mark et al.
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4863727 (1989-09-01), Zimmerman et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 5066584 (1991-11-01), Gyllensten et al.
patent: 5098702 (1992-03-01), Zimmerman et al.
patent: 5206344 (1993-04-01), Katre et al.
Borden, "Interferons: Rationale for Clinical Trials in Neoplastic Disease," Ann. Intern. Med., 91:472-479 (1979).
Buessow et al., "Tumoricidal Activity of an Acute Promyelocytic Leukemis Cell Line (HL-60) is Augmented by Hyman Inteferon Alpha," Leukemia Res., 8:801-811 (1984).
Carswell et al., "An endotoxin-induced serum factor that causes necrosis of tumors", PNAS (USA), 72:3666-3670 (Sep., 1975).
DeClercq et al., "Synergism in the Antitumor Effects of Type 1 and Type II Interferon in Mice Inoculated With Leukemia L1210 Cells," Cancer Letters, 15:223-228 (1982).
Dempsey et al., "The Differential Effects of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human Natural Killer Activity", J. Immunol., 129:2504 (Dec. 1982).
Devos et al., "Molecular Cloning of Human Interleukin 2 cDNA and its Expression in E. coli", Nucl. Acids Res., 11:4307 (1983).
Fleishman, "Potentiation of the Direct Anticellular Activity of Mouse Interferons: Mutal Synergism and Interferon Concentration Dependence", Cancer Res., 42:869-875 (Mar. 1982).
Gray et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity", Nature, 312:721 (Dec. 1984).
Haranaka et al., "Antitumor Activity of Murine Tumor Necrosis Factor (TNF) Against Transplanted Murine Tumors and Heterotransplanted Human Tumors in Nude Mice", Int. J. Cancer, 34:263 (1984).
Haranaka et al., "Cytotoxic Activity of Tumor Necrosis Factor (TNF) on Human Cancer Cells in vitro," Jap. J. Exp. Med., 51:191-194 (1981).
Lopez-Botet et al., "Interleukin 2 and interferon-.gamma. are not sufficient to induce natural killer-like activity in human T cell clones," Eur. J. Immuno., 14:1137-1141 (1984).
Matsunaga et al., "Augmentation of In Vitro Cytotoxicity and In Vivo Tumor-Inhibition by Combined Use of Lymphotoxin-Containing Supernatants and Antitumor Drugs", Cancer Letters, 20:21 (1983).
Matthews et al., "Tumor-Necrosis Factor from the Rabbit. III. Relationship to Interferons," Chem. Abstr., 92:108513h (1980).
Metz, "Interferon and Interferon Inducers," Adv. Drug Res., 10:101-156 (1975).
Morgan et al., "Selective in vitro Growth of T Lymphocytes from Normal Human Bone Marrows," Science, 193:1007-1008 (Sep. 1976).
Mule et al., "Adoptive Immunotherapy of Established Pulmonary, Metastass with LAK Cells and Recombinatn Interleukin-2," Science, 225:1487-1489 (Sep. 1984).
Papermaster et al., "Lymphokine Adjuvant Therapy: Bioassay of Human Lymphokine Fractions in a Mouse Tumor Model", Hum. Lymphokines; Khan et al., (ed), pp. 459-477 (Jun. 30, 1982).
Paucker et al., "Quantitative Studies on Viral Interference in Suspended L Cells III. Effect of interfering Viruses and Interferon on the Growth Rate of Cells," Virology, 17:324 (1962).
Pennica et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin", Nature, 312:724 (Dec. 1984).
Rosenberg et al., "Observations on the Systemic Administrtion of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer", N. Eng. J. Med., 313:1485 (Dec. 1985).
Rosenberg et al., "A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes", Science, 233:1318 (Sep. 1986).
Sande et al., "Antimicrobial Agents," in the Pharmacological Basis of Therapeutics, Goodman et al., (eds.), MacMillan Publishing: N.Y., pp. 1080-1105 (1980).
Shalaby et al., "In Vivo Augmentation of Natural Killer Activity by Combined Treatment with Recombinant Gamma Interferon and Interleukin-2", J. Inteferon Res., 5:571 (1985).
Shirai et al., "Cloning and expression in Escherichia coli of the gene for human tumour necrosis factors", Nature, 313:803 (Feb. 1985).
Svedersky et al., "Augmenttion of Human Natural Cell-Mediated Cytotoxicity by Recombinant Human Interleukin 2", J. Immunol., 133:714 (Aug. 1984).
Taniguchi et al., "Structure and expression of a cloned cDNA for human interleukin-2", Nature, 302:305 (Mar. 1983).
Wang et al., "Site-Specific Mutagenesis of the Human Interleukin-2 Gene: Structure-Function Analysis of the Cysteine Residues", Science, 224:1431 (Jun. 1984).
Wang et al., "Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor," Science, 228:149-154 (Apr. 1985).
Williams et al., "In vitro Synergism between Inteferons and Human Lymphotoxin: Enhancement of Lymphotoxin-Induced Target Cell Killing", J. Immunol., 130:518 (Feb. 1983).
Williamson et al., "Human tumor necrosis factor produced by human B-cell lines: Synergistic cytotoxic interaction with human interferon", PNAS (USA), 80:5397 (Sep. 1983).
Winkelhake et al., "Immunological Block to Synthetic .alpha.-Melanocyte-stimulating Hormone: Melanocyte Interaction by Antibodies Isolated from Cell-Column Immunoadsorbents", Cancer Res., 39:3058-3064 (Aug. 1979).
Winkelhake Jeffrey L.
Zimmerman Robert
Blackburn Robert P.
Cetus Oncology Corporation
Gass David A.
McGarrigle Philip L.
Stone Jacqueline
LandOfFree
Combination therapy using interleukin-2 and tumor necrosis facto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using interleukin-2 and tumor necrosis facto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using interleukin-2 and tumor necrosis facto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1842889